WA
BIVV

Winfield Associates’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Winfield Associates’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25
Closed -$2K – 796
2017
Q4 		$2K Hold
25
– – ﹤0.01% 721
2017
Q3 		$1K Hold
25
– – ﹤0.01% 770
2017
Q2 		$2K Hold
25
– – ﹤0.01% 739
2017
Q1 		$1K Buy
+25
New +$1.23K ﹤0.01% 733

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Winfield Associates's BIVV Position: Q1 2018 in Review

Winfield Associates sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 25 shares — an estimated $2K sold.

Winfield Associates first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $2K in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Winfield Associates reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 25 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $2K.
  • Winfield Associates first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Winfield Associates's Bioverativ Inc. Common Stock position peaked at $2K in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.